$STE
STERIS plc Stock $ste

$ste Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000175789821000027 Filed on August 09, 2021

Income Statement

Concept	2021 Q2	2020 Q2
Revenue	$968.4M	$668.9M
YoY Change	44.77%	-4.0%
Cost Of Revenue	$542.1M	$381.5M
YoY Change	42.09%	-2.15%
Gross Profit	$426.3M	$287.4M
YoY Change	48.33%	-6.36%
Gross Profit Margin	44.02%	42.96%
Selling, General & Admin	$393.8M	$155.2M
YoY Change	153.76%	-13.21%
% of Gross Profit	92.37%	53.99%
Research & Development	$18.19M	$16.23M
YoY Change	12.08%	4.15%
% of Gross Profit	4.27%	5.65%
Depreciation & Amortization	$83.62M	$48.95M
YoY Change	70.82%	3.93%
% of Gross Profit	19.62%	17.03%
Operating Expenses	$412.0M	$171.6M
YoY Change	140.11%	-12.36%
Operating Profit	$14.32M	$115.8M
YoY Change	-87.63%	5.2%
Interest Expense	$21.81M	$9.492M
YoY Change	129.79%	-9.12%
% of Operating Profit	152.28%	8.2%
Other Income/Expense, Net	-$43.30M	-$7.203M
YoY Change	501.15%	-32.54%
Pretax Income	-$28.98M	$108.6M
YoY Change	-126.68%	9.26%
Income Tax	-$7.075M	$19.08M
% Of Pretax Income		17.57%
Net Earnings	-$21.81M	$89.60M
YoY Change	-124.34%	4.95%
Net Earnings / Revenue	-2.25%	13.39%
Basic Earnings Per Share	-$0.24	$1.05
Diluted Earnings Per Share	-$0.24	$1.05
COMMON SHARES
Basic Shares Outstanding	90.15M shares	84.96M shares
Diluted Shares Outstanding	90.99M shares	85.68M shares

Balance Sheet

Concept	2021 Q2	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$534.8M	$255.6M
YoY Change	109.22%	7.35%
Cash & Equivalents	$534.8M	$255.6M
Short-Term Investments
Other Short-Term Assets	$136.6M	$61.40M
YoY Change	122.47%	-2.54%
Inventory	$593.1M	$277.0M
Prepaid Expenses
Receivables	$743.4M	$503.2M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$2.008B	$1.097B
YoY Change	83.01%	5.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.499B	$1.148B
YoY Change	30.61%	8.9%
Goodwill	$5.287B	$2.372B
YoY Change	122.89%	1.04%
Intangibles	$3.048B	$551.5M
YoY Change	452.71%	-8.41%
Long-Term Investments
YoY Change
Other Assets	$51.45M	$51.97M
YoY Change	-1.01%	-12.21%
Total Long-Term Assets	$10.09B	$4.267B
YoY Change	136.55%	1.94%
TOTAL ASSETS
Total Short-Term Assets	$2.008B	$1.097B
Total Long-Term Assets	$10.09B	$4.267B
Total Assets	$12.10B	$5.364B
YoY Change	125.6%	2.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$232.2M	$133.5M
YoY Change	73.88%	-1.44%
Accrued Expenses	$300.8M	$180.2M
YoY Change	66.91%	-1.43%
Deferred Revenue
YoY Change
Short-Term Debt	$6.875M	$35.00M
YoY Change	-80.36%
Long-Term Debt Due	$6.875M
YoY Change
Total Short-Term Liabilities	$1.145B	$479.5M
YoY Change	138.77%	10.81%
LONG-TERM LIABILITIES
Long-Term Debt	$3.257B	$1.022B
YoY Change	218.61%	-15.52%
Other Long-Term Liabilities	$86.04M	$86.39M
YoY Change	-0.4%	1.55%
Total Long-Term Liabilities	$3.343B	$1.109B
YoY Change	201.55%	-14.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.145B	$479.5M
Total Long-Term Liabilities	$3.343B	$1.109B
Total Liabilities	$5.516B	$1.874B
YoY Change	194.31%	-5.57%
SHAREHOLDERS EQUITY
Retained Earnings	$1.875B	$1.700B
YoY Change	10.27%	21.65%
Common Stock	$4.737B	$1.983B
YoY Change	138.87%	-0.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.575B	$3.475B
YoY Change
Total Liabilities & Shareholders Equity	$12.10B	$5.364B
YoY Change	125.6%	2.57%

Cashflow Statement

Concept	2021 Q2	2020 Q2
OPERATING ACTIVITIES
Net Income	-$21.81M	$89.60M
YoY Change	-124.34%	4.95%
Depreciation, Depletion And Amortization	$83.62M	$48.95M
YoY Change	70.82%	3.93%
Cash From Operating Activities	$97.43M	$134.1M
YoY Change	-27.36%	22.67%
INVESTING ACTIVITIES
Capital Expenditures	$56.40M	$66.86M
YoY Change	-15.65%	34.28%
Acquisitions	$547.4M	$0.00
YoY Change		-100.0%
Other Investing Activities	-$547.1M	$100.0K
YoY Change	-547236.0%
Cash From Investing Activities	-$603.5M	-$66.72M
YoY Change	804.52%	-20.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$10.67M	$14.30M
YoY Change	-25.36%	-3.96%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$818.8M	-$134.0M
YoY Change	-711.05%	1661.54%
NET CHANGE
Cash From Operating Activities	$97.43M	$134.1M
Cash From Investing Activities	-$603.5M	-$66.72M
Cash From Financing Activities	$818.8M	-$134.0M
Net Change In Cash	$314.2M	-$63.95M
YoY Change	-591.36%	-466.83%
FREE CASH FLOW
Cash From Operating Activities	$97.43M	$134.1M
Capital Expenditures	$56.40M	$66.86M
Free Cash Flow	$41.03M	$67.26M
YoY Change	-39.0%	12.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q2	dei	Entity Registrant Name EntityRegistrantName	STERIS plc
CY2021Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001757898
CY2021Q2	dei	Document Type DocumentType	10-Q
CY2021Q2	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
CY2021Q2	dei	Amendment Flag AmendmentFlag	false
CY2021Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2021Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q2	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	99758941	shares
CY2021Q2	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q2	dei	Entity File Number EntityFileNumber	001-38848
CY2021Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L2
CY2021Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1455064
CY2021Q2	dei	Local Phone Number LocalPhoneNumber	1 232 2000
CY2021Q2	dei	City Area Code CityAreaCode	353
CY2021Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	17657000	USD
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	11355000	USD
CY2021Q2	ste	Aggregate Amountof Shares Authorized AggregateAmountofSharesAuthorized	500000000	USD
CY2021Q1	ste	Aggregate Amountof Shares Authorized AggregateAmountofSharesAuthorized	500000000	USD
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	500000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	500000000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	99746000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	85353000	shares
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax	174000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax	174000	USD
CY2021Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.40
CY2020Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.37
CY2021Q2	dei	Document Type DocumentType	10-Q
CY2021Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q2	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
CY2021Q2	dei	Entity File Number EntityFileNumber	001-38848
CY2021Q2	dei	Entity Registrant Name EntityRegistrantName	STERIS plc
CY2021Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L2
CY2021Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1455064
CY2021Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	70 Sir John Rogerson's Quay,
CY2021Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Dublin 2,
CY2021Q2	dei	Entity Address Country EntityAddressCountry	IE
CY2021Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	D02 R296
CY2021Q2	dei	City Area Code CityAreaCode	353
CY2021Q2	dei	Local Phone Number LocalPhoneNumber	1 232 2000
CY2021Q2	dei	Security12b Title Security12bTitle	Ordinary Shares, $0.001 par value
CY2021Q2	dei	Trading Symbol TradingSymbol	STE
CY2021Q2	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2021Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q2	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021Q2	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q2	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	99758941	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	534774000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	220531000	USD
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	17657000	USD
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	11355000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	743420000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	609406000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	593067000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	315067000	USD
CY2021Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	136599000	USD
CY2021Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	66750000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	2007860000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	1211754000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1499448000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1235400000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	207341000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	150142000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	5286594000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	3026049000	USD
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3048319000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	898406000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	51445000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	52720000	USD
CY2021Q2	us-gaap	Assets Assets	12101007000	USD
CY2021Q1	us-gaap	Assets Assets	6574471000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	232186000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	156950000	USD
CY2021Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	8516000	USD
CY2021Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	27561000	USD
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	193167000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	150078000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	37033000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	22774000	USD
CY2021Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	168000000	USD
CY2021Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
CY2021Q2	ste	Convertible Debt Premium Liability ConvertibleDebtPremiumLiability	198478000	USD
CY2021Q1	ste	Convertible Debt Premium Liability ConvertibleDebtPremiumLiability	0	USD
CY2021Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	6875000	USD
CY2021Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	300770000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	220557000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1145025000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	577920000	USD
CY2021Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3256714000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1650540000	USD
CY2021Q2	us-gaap	Deferred Income Taxes And Other Tax Liabilities Noncurrent DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent	856899000	USD
CY2021Q1	us-gaap	Deferred Income Taxes And Other Tax Liabilities Noncurrent DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent	236860000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	171314000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	129673000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	86040000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	88010000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	5515992000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	2683003000	USD
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	ste	Aggregate Amountof Shares Authorized AggregateAmountofSharesAuthorized	500000000	USD
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	99746000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	85353000	shares
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	4736838000	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	2002825000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1874559000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1939408000	USD
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-36817000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-61243000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	6574580000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	3880990000	USD
CY2021Q2	us-gaap	Minority Interest MinorityInterest	10435000	USD
CY2021Q1	us-gaap	Minority Interest MinorityInterest	10478000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6585015000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3891468000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12101007000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6574471000	USD
CY2021Q2	us-gaap	Revenues Revenues	968422000	USD
CY2020Q2	us-gaap	Revenues Revenues	668932000	USD
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	542140000	USD
CY2020Q2	us-gaap	Cost Of Revenue CostOfRevenue	381548000	USD
CY2021Q2	us-gaap	Gross Profit GrossProfit	426282000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	287384000	USD
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	393752000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	155170000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18192000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16231000	USD
CY2021Q2	us-gaap	Restructuring Costs RestructuringCosts	14000	USD
CY2020Q2	us-gaap	Restructuring Costs RestructuringCosts	166000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	411958000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	171567000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	14324000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	115817000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	21812000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	9492000	USD
CY2021Q2	ste	Fair Value Adjustment Related To Convertible Debt Liability FairValueAdjustmentRelatedToConvertibleDebtLiability	22923000	USD
CY2020Q2	ste	Fair Value Adjustment Related To Convertible Debt Liability FairValueAdjustmentRelatedToConvertibleDebtLiability	0	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1434000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2289000	USD
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43301000	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7203000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28977000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	108614000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7075000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19083000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-21902000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	89531000	USD
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-95000	USD
CY2020Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-66000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-21807000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	89597000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.05
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.05
CY2021Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.40
CY2020Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.37
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-21902000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	89531000	USD
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-95000	USD
CY2020Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-66000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-21807000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	89597000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax	174000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax	174000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	-507000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	-510000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	24933000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	27619000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	24426000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	27109000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2619000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	116706000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-21902000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	89531000	USD
CY2021Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	83621000	USD
CY2020Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	48954000	USD
CY2021Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	456000	USD
CY2020Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1814000	USD
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	26600000	USD
CY2020Q2	us-gaap	Share Based Compensation ShareBasedCompensation	5962000	USD
CY2021Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-824000	USD
CY2020Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-237000	USD
CY2021Q2	ste	Loss On Sale Of Business LossOnSaleOfBusiness	-419000	USD
CY2020Q2	ste	Loss On Sale Of Business LossOnSaleOfBusiness	-10000	USD
CY2021Q2	ste	Fair Value Adjustment Related To Convertible Debt Liability FairValueAdjustmentRelatedToConvertibleDebtLiability	22923000	USD
CY2020Q2	ste	Fair Value Adjustment Related To Convertible Debt Liability FairValueAdjustmentRelatedToConvertibleDebtLiability	0	USD
CY2021Q2	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2334000	USD
CY2020Q2	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-6842000	USD
CY2021Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-41732000	USD
CY2020Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-84665000	USD
CY2021Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1660000	USD
CY2020Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	28830000	USD
CY2021Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6747000	USD
CY2020Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6729000	USD
CY2021Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4614000	USD
CY2020Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-17011000	USD
CY2021Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-41892000	USD
CY2020Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-47695000	USD
CY2021Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	97426000	USD
CY2020Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	134122000	USD
CY2021Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	56396000	USD
CY2020Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	66861000	USD
CY2021Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	217000	USD
CY2020Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	137000	USD
CY2021Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	547353000	USD
CY2020Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2021Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-603532000	USD
CY2020Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-66724000	USD
CY2021Q2	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	1350000000	USD
CY2020Q2	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	USD
CY2021Q2	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	650000000	USD
CY2020Q2	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
CY2021Q2	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	125000000	USD
CY2020Q2	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	USD
CY2021Q2	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	-721284000	USD
CY2020Q2	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	0	USD
CY2021Q2	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-249421000	USD
CY2020Q2	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-95837000	USD
CY2021Q2	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	17227000	USD
CY2020Q2	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2021Q2	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	25150000	USD
CY2020Q2	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	21000	USD
CY2021Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	10670000	USD
CY2020Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	14296000	USD
CY2021Q2	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	34148000	USD
CY2020Q2	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	31471000	USD
CY2021Q2	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2020Q2	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	2258000	USD
CY2021Q2	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	1710000	USD
CY2020Q2	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	5367000	USD
CY2021Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	818810000	USD
CY2020Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-134000000	USD
CY2021Q2	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	1539000	USD
CY2020Q2	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2648000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	314243000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-63954000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	220531000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	319581000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	534774000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	255627000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3891468000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-21902000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	24426000	USD
CY2021Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	10670000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	28299000	USD
CY2021Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.40
CY2021Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	34148000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2689317000	USD
CY2021Q2	ste	Consideration Related To Equity Component Of Cantel Convertible Debt ConsiderationRelatedToEquityComponentOfCantelConvertibleDebt	175555000	USD
CY2021Q2	ste	Consideration Related To Cantel Equity Compensation Programs ConsiderationRelatedToCantelEquityCompensationPrograms	18173000	USD
CY2021Q2	ste	Reclassification To Cantel Convertible Debt Premium Liability ReclassificationToCantelConvertibleDebtPremiumLiability	175555000	USD
CY2021Q2	ste	Increase Decrease In Noncontrolling Interests Other IncreaseDecreaseInNoncontrollingInterestsOther	-52000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6585015000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3418210000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	89531000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	27109000	USD
CY2020Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	14296000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11256000	USD
CY2020Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.37
CY2020Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	31471000	USD
CY2020Q2	ste	Noncontrolling Interest Increase From Contributions To Noncontrolling Interest Holders NoncontrollingInterestIncreaseFromContributionsToNoncontrollingInterestHolders	2258000	USD
CY2020Q2	ste	Increase Decrease In Noncontrolling Interests Other IncreaseDecreaseInNoncontrollingInterestsOther	-9000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3502606000	USD
CY2021Q2	us-gaap	Nature Of Operations NatureOfOperations	Nature of Operations and Summary of Significant Accounting Policies<div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">STERIS is a leading global provider of products and services that meet the needs of healthcare growth areas: procedures, devices, pharmaceuticals and dental. Ou</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. We offer our Customers a unique mix of innovative consumable products, such as detergents, gastrointestinal ("GI") endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, dental instruments and tools, instrument and scope repair solutions, laboratory testing services, outsourced reprocessing, and capital equipment products, such as sterilizers and surgical tables, automated endoscope reprocessors, and connectivity solutions such as operating room (“OR”) integrati</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2021, we completed our previously announced acquisition of Cantel Medical Corp. Refer to note 2 titled, "Business Acquisitions" for additional information regarding this acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2021 dated May 28, 2021. The Consolidated Balance Sheet at March 31, 2021 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three month period ended June 30, 2021 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition and Associated Liabilities</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At June 30, 2021, assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our Healthcare and Life Sciences segments, service revenues consist of revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or Group Purchasing Organization ("GPO") agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancelable </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first three months of fiscal </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, $35,722 of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the March 31, 2021 deferred revenue balance was recorded as revenue. During the first three months of fiscal 2021, $30,804 of the March 31, 2020 deferred revenue balance was recorded as revenue.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Liabilities</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of June 30, 2021, the transaction price allocated to remaining performance obligations was approximately $1,371,500. We expect to recognize approximately 55% of the transaction price within one year and approximately 37% beyond one year. The remainder has yet to be scheduled for delivery. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Impacting the Company</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently Issued Accounting Standards Impacting the Company are presented in the following table:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.331%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Adoption</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="27" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standards that have been adopted in fiscal 2022</span></td></tr><tr style="height:5pt"><td colspan="27" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2019-12 "Income Taxes (Topic 740)"</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard provides final guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The guidance simplifies accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. .</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Quarter Fiscal 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We adopted this standard effective April 1, 2021 with no material impact to our consolidated financial statements.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2020-06 "Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)"</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This standard simplifies the accounting for convertible instruments and its application of the derivatives scope exception for contracts in an entity’s own equity. The standard reduces the number of accounting models that require separating embedded conversion features from convertible instruments. As a result, only conversion features accounted for under the substantial premium model and those that require bifurcation will be accounted for separately. For contracts in an entity’s own equity, the new standard eliminates some of the current requirements for equity classification. The standard also addresses how convertible instruments are accounted for in the diluted earnings per share calculation and requires enhanced disclosures about the terms of convertible instruments and contracts in an entity’s own equity. </span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Quarter Fiscal 2022</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We adopted this standard effective April 1, 2021 and applied it to our accounting for the convertible debt assumed in the acquisition of Cantel Medical Corp. ("Cantel"). </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2021 dated May 28, 2021. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2021.</span></div>
CY2021Q2	ste	Consideration Related To Equity Component Of Convertible Debt ConsiderationRelatedToEquityComponentOfConvertibleDebt	175555000	USD
CY2021Q2	ste	Cantel Acquisition Assumed Debt Obligations CantelAcquisitionAssumedDebtObligations	721284000	USD
CY2021Q2	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three month period ended June 30, 2021 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2022.</span></div>
CY2021Q2	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	35722000	USD
CY2020Q2	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	30804000	USD
CY2021Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1371500000	USD
CY2021Q2	dei	Entity Number Of Employees EntityNumberOfEmployees	3700
CY2021Q2	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	716412000	USD
CY2021Q2	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1	14000	USD
CY2021Q2	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	2689317000	USD
CY2021Q2	ste	Consideration Transferred Equity Awards Issued And Issuable ConsiderationTransferredEquityAwardsIssuedAndIssuable	18173000	USD
CY2021Q2	ste	Contingent Consideration Liability Assumed In Cantel Combination ContingentConsiderationLiabilityAssumedInCantelCombination	25000000	USD
CY2021Q2	ste	Net Sales Attributable To Cantel NetSalesAttributableToCantel	101758000	USD
CY2021Q2	ste	Operating Loss Income Attributable To Cantel OperatingLossIncomeAttributableToCantel	-133190000	USD
CY2021Q2	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1173519000	USD
CY2020Q2	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	869874000	USD
CY2021Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	93635000	USD
CY2020Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-90382000	USD
CY2021Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	183233000	USD
CY2021Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	103939000	USD
CY2021Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	72119000	USD
CY2021Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	54283000	USD
CY2021Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	376381000	USD
CY2021Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	176623000	USD
CY2021Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	38666000	USD
CY2021Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	19778000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	593067000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	315067000	USD
CY2021Q2	us-gaap	Land Land	84154000	USD
CY2021Q1	us-gaap	Land Land	69477000	USD
CY2021Q2	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	662527000	USD
CY2021Q1	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	567132000	USD
CY2021Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	866896000	USD
CY2021Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	779044000	USD
CY2021Q2	ste	Capitalized Computer Hardware Software Gross CapitalizedComputerHardwareSoftwareGross	224584000	USD
CY2021Q1	ste	Capitalized Computer Hardware Software Gross CapitalizedComputerHardwareSoftwareGross	193222000	USD
CY2021Q2	us-gaap	Materials Supplies And Other MaterialsSuppliesAndOther	577724000	USD
CY2021Q1	us-gaap	Materials Supplies And Other MaterialsSuppliesAndOther	565681000	USD
CY2021Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	274414000	USD
CY2021Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	211381000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2690299000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2385937000	USD
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1190851000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1150537000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1499448000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1235400000	USD
CY2021Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	6875000	USD
CY2021Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2021Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	6875000	USD
CY2021Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2021Q2	us-gaap	Senior Notes SeniorNotes	862719000	USD
CY2021Q1	us-gaap	Senior Notes SeniorNotes	860308000	USD
CY2021Q2	us-gaap	Line Of Credit LineOfCredit	0	USD
CY2021Q1	us-gaap	Line Of Credit LineOfCredit	247423000	USD
CY2021Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	28160000	USD
CY2021Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	7191000	USD
CY2021Q2	ste	Term Loan TermLoan	418125000	USD
CY2021Q1	ste	Term Loan TermLoan	550000000	USD
CY2021Q2	ste	Delayed Draw Term Loan DelayedDrawTermLoan	650000000	USD
CY2021Q1	ste	Delayed Draw Term Loan DelayedDrawTermLoan	0	USD
CY2021Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	4030000	USD
CY2021Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	0	USD
CY2021Q2	us-gaap	Long Term Debt LongTermDebt	3256714000	USD
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	1650540000	USD
CY2021Q2	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	3431589000	USD
CY2021Q1	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	1650540000	USD
CY2021Q2	ste	Delayed Draw Term Loan DelayedDrawTermLoan	650000000	USD
CY2021Q2	ste	Business Acquisition Shares Received Per Ordinary Share BusinessAcquisitionSharesReceivedPerOrdinaryShare	0.33787	shares
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	ste	Debt Instrument Convertible Units Of Property Reference DebtInstrumentConvertibleUnitsOfPropertyReference	25.0843
CY2021Q2	ste	Debt Instrument Convertible Parent Shares DebtInstrumentConvertibleParentShares	8.4752	shares
CY2021Q2	ste	Debt Instrument Convertible Cash Per One Thousand Dollars Ratio DebtInstrumentConvertibleCashPerOneThousandDollarsRatio	424.68
CY2021Q2	ste	Debt Instrument Convertible Increase In Conversion Rate Shares DebtInstrumentConvertibleIncreaseInConversionRateShares	0.9931	shares
CY2021Q2	ste	Debt Instrument Convertible Stock Price DebtInstrumentConvertibleStockPrice	81.3520
CY2021Q2	ste	Consideration Related To Equity Component Of Convertible Debt ConsiderationRelatedToEquityComponentOfConvertibleDebt	175555000	USD
CY2021Q2	ste	Convertible Debt Premium Liability ConvertibleDebtPremiumLiability	198478000	USD
CY2021Q2	ste	Long Term Debt Daily Volume Weighted Average Price LongTermDebtDailyVolumeWeightedAveragePrice	208.45
CY2021Q2	ste	Long Term Debt Increase Decrease In Daily Volume Weighted Average Price Percent LongTermDebtIncreaseDecreaseInDailyVolumeWeightedAveragePricePercent	0.050
CY2021Q2	ste	Long Term Debt Increase Decrease In Non Operating Expenses LongTermDebtIncreaseDecreaseInNonOperatingExpenses	11300000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths	168000000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	142875000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	60000000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	165938000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	502500000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	2416406000	USD
CY2021Q2	ste	Long Term Debt Excluding Deferred Financing Fees LongTermDebtExcludingDeferredFinancingFees	3455719000	USD
CY2021Q2	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	112225000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	47157000	USD
CY2021Q2	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	20081000	USD
CY2021Q1	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	12389000	USD
CY2021Q2	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	40759000	USD
CY2021Q1	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	62530000	USD
CY2021Q2	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	15945000	USD
CY2021Q1	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	24022000	USD
CY2021Q2	us-gaap	Other Postretirement Benefits Payable Current And Noncurrent OtherPostretirementBenefitsPayableCurrentAndNoncurrent	1326000	USD
CY2021Q1	us-gaap	Other Postretirement Benefits Payable Current And Noncurrent OtherPostretirementBenefitsPayableCurrentAndNoncurrent	1326000	USD
CY2021Q2	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current And Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent	2831000	USD
CY2021Q1	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current And Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent	2654000	USD
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	193167000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	150078000	USD
CY2021Q2	us-gaap	Deferred Revenue DeferredRevenue	102133000	USD
CY2021Q1	us-gaap	Deferred Revenue DeferredRevenue	62492000	USD
CY2021Q2	ste	Serviceliabilities Serviceliabilities	44852000	USD
CY2021Q1	ste	Serviceliabilities Serviceliabilities	46720000	USD
CY2021Q2	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	9068000	USD
CY2021Q1	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	8095000	USD
CY2021Q2	us-gaap	Accrued Sales Commission Current And Noncurrent AccruedSalesCommissionCurrentAndNoncurrent	31851000	USD
CY2021Q1	us-gaap	Accrued Sales Commission Current And Noncurrent AccruedSalesCommissionCurrentAndNoncurrent	27348000	USD
CY2021Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	13633000	USD
CY2021Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	9406000	USD
CY2021Q2	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	1199000	USD
CY2021Q1	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	1193000	USD
CY2021Q2	ste	Accrued Interest AccruedInterest	16285000	USD
CY2021Q1	ste	Accrued Interest AccruedInterest	7751000	USD
CY2021Q2	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	81749000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	57552000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	300770000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	220557000	USD
CY2021Q2	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	17295000	USD
CY2021Q1	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	17295000	USD
CY2021Q2	us-gaap	Other Postretirement Benefits Payable Noncurrent OtherPostretirementBenefitsPayableNoncurrent	8279000	USD
CY2021Q1	us-gaap	Other Postretirement Benefits Payable Noncurrent OtherPostretirementBenefitsPayableNoncurrent	8690000	USD
CY2021Q2	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	4020000	USD
CY2021Q1	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	3748000	USD
CY2021Q2	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	1733000	USD
CY2021Q1	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2353000	USD
CY2021Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	13241000	USD
CY2021Q1	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	13241000	USD
CY2021Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	12361000	USD
CY2021Q1	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	12137000	USD
CY2021Q2	ste	Longtermliabilitiesother Longtermliabilitiesother	29111000	USD
CY2021Q1	ste	Longtermliabilitiesother Longtermliabilitiesother	30546000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	86040000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	88010000	USD
CY2021Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.244
CY2020Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.176
CY2021Q2	us-gaap	Income Tax Examination Estimate Of Possible Loss IncomeTaxExaminationEstimateOfPossibleLoss	12000000	USD
CY2021Q2	ste	Uncertain Tax Liability Resulting From Irs Notice UncertainTaxLiabilityResultingFromIRSNotice	50000000	USD
CY2021Q2	ste	Amortizationandimpairmentofacquiredintangibleassets Amortizationandimpairmentofacquiredintangibleassets	41741000	USD
CY2020Q2	ste	Amortizationandimpairmentofacquiredintangibleassets Amortizationandimpairmentofacquiredintangibleassets	17500000	USD
CY2021Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	140996000	USD
CY2020Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1286000	USD
CY2021Q2	ste	Tax Restructuring Costs TaxRestructuringCosts	-49000	USD
CY2020Q2	ste	Tax Restructuring Costs TaxRestructuringCosts	170000	USD
CY2021Q2	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-419000	USD
CY2020Q2	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-10000	USD
CY2021Q2	ste	Amortizationofinventoryandpropertystepuptofairvalue Amortizationofinventoryandpropertystepuptofairvalue	24789000	USD
CY2020Q2	ste	Amortizationofinventoryandpropertystepuptofairvalue Amortizationofinventoryandpropertystepuptofairvalue	603000	USD
CY2021Q2	ste	Covid19incrementalcosts COVID19incrementalcosts	0	USD
CY2020Q2	ste	Covid19incrementalcosts COVID19incrementalcosts	8670000	USD
CY2021Q2	us-gaap	Restructuring Charges RestructuringCharges	14000	USD
CY2020Q2	us-gaap	Restructuring Charges RestructuringCharges	166000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	14324000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	115817000	USD
CY2021Q2	us-gaap	Revenues Revenues	968422000	USD
CY2020Q2	us-gaap	Revenues Revenues	668932000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1499448000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1235400000	USD
CY2021Q2	us-gaap	Assets Assets	12101007000	USD
CY2021Q1	us-gaap	Assets Assets	6574471000	USD
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90152000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	84959000	shares
CY2021Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	840000	shares
CY2020Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	717000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90992000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85676000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q2	ste	Deferred Ordinary Shares DeferredOrdinaryShares	25000	shares
CY2019Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	78979000	USD
CY2019Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	300000000	USD
CY2021Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	333932000	USD
CY2020Q2	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	35000	shares
CY2020Q2	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	5047000	USD
CY2021Q2	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	59648	shares
CY2021Q2	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	10670000	USD
CY2020Q2	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	63150	shares
CY2020Q2	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	9248000	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3275133	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0116
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0046
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0097
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0096
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.2441
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.2304
CY2021Q2	ste	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.0285
CY2020Q2	ste	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.0278
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1637047	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	112.03
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	200684	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	210.31
CY2021Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	36853	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	50.23
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1800878	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	124.25
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	148573000	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1155980	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	96.73
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M24D
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	126658000	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	621487	shares
CY2021Q2	ste	Common Stock Fair Market Value Per Share CommonStockFairMarketValuePerShare	206.30
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5469000	USD
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	9581000	USD
CY2021Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1710000	USD
CY2020Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5367000	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	36.24
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	27.44
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	67599000	USD
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M24D
CY2021Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	9406000	USD
CY2021Q2	us-gaap	Standard Product Warranty Accrual Additions From Business Acquisition StandardProductWarrantyAccrualAdditionsFromBusinessAcquisition	4769000	USD
CY2021Q2	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	3530000	USD
CY2021Q2	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	4072000	USD
CY2021Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	13633000	USD
CY2021Q2	ste	Nonderivative Net Investment Hedge NonderivativeNetInvestmentHedge	50102000	USD
CY2021Q2	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-16000	USD
CY2020Q2	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	309000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	19642000	USD
CY2021Q2	ste	Contingent Consideration Liability Assumed In Cantel Combination ContingentConsiderationLiabilityAssumedInCantelCombination	25000000	USD
CY2021Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	19805000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-61243000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	25524000	USD
CY2021Q2	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-1098000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	24426000	USD
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-36817000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-235463000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	27937000	USD
CY2020Q2	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-828000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	27109000	USD
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-208354000	USD

Files In Submission

Name	View Source	Status
0001757898-21-000027-index-headers.html	Edgar Link	pending
0001757898-21-000027-index.html	Edgar Link	pending
0001757898-21-000027.txt	Edgar Link	pending
0001757898-21-000027-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ste-20210630.htm	Edgar Link	pending
ste-20210630.xsd	Edgar Link	pending
ste-20210630_cal.xml	Edgar Link	unprocessable
ste-20210630_def.xml	Edgar Link	unprocessable
ste-20210630_htm.xml	Edgar Link	completed
ste-20210630_lab.xml	Edgar Link	unprocessable
ste-20210630_pre.xml	Edgar Link	unprocessable
ste06302021ex151.htm	Edgar Link	pending
ste06302021ex221.htm	Edgar Link	pending
ste06302021ex311.htm	Edgar Link	pending
ste06302021ex312.htm	Edgar Link	pending
ste06302021ex321.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STE
STERIS plc Stock $ste

2021 Q2 Form 10-Q Financial Statement

#000175789821000027 Filed on August 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STE STERIS plc Stock $ste

2021 Q2 Form 10-Q Financial Statement

#000175789821000027 Filed on August 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STE
STERIS plc Stock $ste